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Abstract
Introduction Several aziridinylbenzoquinone drugs have
undergone clinical trials as potential antitumor drugs. These
bioreductive compounds are designed to kill cells preferentially
within the hypoxia tumor microenvironment. The bioreductive
compound of bis-type naphthoquinone synthesized in our
laboratory, 2-aziridin-1-yl-3-[(2-{2-[(3-aziridin-1-yl-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)thio]ethoxy}ethyl)thio]naphthoquinone
(AZ-1), had the most potent death effect on the breast cancer
cells BC-M1 in our previous screening. In the present study, we
determined that the mechanism of the death effect of BC-M1
cells induced by AZ-1 was mediated by the apoptosis pathway.
Methods We evaluated the cytotoxicity of AZ-1 and the anti-
breast cancer drugs tamoxifen and paclitaxel to BC-M1 cells
and MCF-7 cells by the MTT assay and measured the apoptosis
phenomena by Hoechst 33258 staining for apoptotic bodies.
We also quantified the sub-G1 peak area and the ratio of the
CH2/CH3 peak area of the cell membrane in BC-M1 cells by
flow cytometry and 1H-NMR spectra, respectively.
The apoptosis-related protein expressions, including p53, p21,
the RNA-relating protein T-cell restricted intracellular antigen-
related protein, cyclin-dependent kinase 2 (cell cycle regulating
kinase) and pro-caspase 3, were detected by western blot, and
the caspase-3 enzyme activity was also quantified by an assay
kit.
Results AZ-1 induced two of the breast cancer cell lines, with
IC50 = 0.51 µM in BC-M1 cells and with IC50= 0.57 µM in MCF-
7 cells, and showed less cytotoxicity to normal fibroblast cells
(skin fibroblasts) with IC50= 5.6 µM. There was a 10-fold
difference between two breast cancer cell lines and normal
fibroblasts. Of the two anti-breast cancer drugs, tamoxifen
showed IC50= 0.12 µM to BC-M1 cells and paclitaxel had much
less sensitivity than AZ-1. The expression of p53 protein
increased from 0.5 to 1.0 µM AZ-1 and decreased at 2.0 µM
AZ-1. The p21 protein increased from 0.5 µM AZ-1, with the
highest at 2 µM AZ-1. Regarding the AZ-1 compound-induced
BC-M1 cells mediating the apoptosis pathway, the apoptotic
body formation, the sub-G1 peak area, the ratio of CH2/CH3 of
phospholipids in the cell membrane and the enzyme activity of
caspase-3 were all in direct proportion with the dose-dependent
increase of the concentration of AZ-1. The death effect-related
proteins, including T-cell restricted intracellular antigen-related
protein, cyclin-dependent kinase 2, and pro-caspase-3, all dose-
dependently decreased with AZ-1 concentration.
Conclusions The AZ-1-induced cell death of BC-M1 cells
mediating the apoptosis pathway might be associated with p53
protein expression, and AZ-1 could have the chance to be a
candidate drug for anti-breast cancer following more
experimental evidence, such as animal models.
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Introduction
The bioreductive drugs, aziridinylbenzoquinones, are a
class of compounds designed to exploit one of the features
of solid tumor biology caused by an inadequate blood sup-
ply to the solid tumor; namely, tumor hypoxia. Such regions
generally are resistant to radiation and other oxygen-requir-
ing treatment [1-4]. The ideal bioreductive drug should be
administered as an inactive prodrug that is only activated
AZ-1 = 2-aziridin-1-yl-3-[(2-{2-[(3-aziridin-1-yl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)thio]ethoxy}ethyl)thio]naphthoquinone; cdk = cyclin-dependent 
kinase; DMEM = Dulbecco's modified Eagle's medium; IC50 = inhibition concentration of 50% cell growth; NMR = nuclear magnetic resonance; PBS 
= phosphate-buffered saline; TIAR = T-cell restricted intracellular antigen-related protein.Breast Cancer Research    Vol 7 No 1    Yang et al.
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under low-oxygen conditions by one-electron or two-elec-
tron reductase [5]. The aziridine-substituted benzoqui-
nones such as mitomycin C, RH1, and E09 are three
principal aziridinylquinone-class hypoxia-specific cytotoxins
that are being developed for clinical use [6-8]. These
agents are composed of an aziridinyl moiety on a quinone
structure, and they convert on reductive metabolism to a
bifunctional alkylating species that can cross-link DNA in
the major grove that interacts predominantly on guanine-N7
[9]. These agents probably produce their major cytotoxic
activities through the formation of DNA cross-links.
Tumor tissue with lower oxidative reduction (redox) poten-
tial relative to most normal tissue could increase reductive
activation of these quinone derivatives in the tumor [2]. The
selectivity of bioreductive drugs is therefore governed not
only by the difference in oxygen tension between the tumor
and normal tissue, but also by levels of enzymes catalyzing
bioreductive activation such as DT-diaphorase [4,10,11].
This fact led to the publication in 1990 of the concept of
'enzyme-directed bioreductive development' by Workman
and Walton [12].
In many cases, the biological activity of quinone is attrib-
uted to the ability of accepted electrons to form the corre-
sponding radical anion or dianion species. A quinone
moiety substituted with aziridine has been shown to be a
potent alkylating agent as a result of bioreduction by the
one-electron reducing enzymes (e.g. NADPH cytochrome
P450 reductase, cytochrome b5 reductase) or by two-elec-
tron reducing enzymes ([NADP]H oxidoreductase, NQO1)
to form the corresponding aziridinyl hydroquinone [13-15].
The hydroquinone moiety in the corresponding aziridinyl
hydroquinone effectively changes the pK value of the aziri-
dine ring such that it is protonated and becomes activated
toward nucleophilic attack under physiological pH.
In previous work in our laboratory, we biosynthesized the
bis-type of bioreductive aziridinylnaphthoquinone series
compounds and evaluated their anti-cancer activity
[16,17]. In the case of di-aziridinyl-substituted quinone, this
highly cytotoxic bifunctional alkylating agent can cross-link
DNA in cells that results in induction of a complex cellular
mechanism leading to cell death by apoptosis or necrosis
[18]. Based on our previous results, the compound 2-aziri-
din-1-yl-3-[(2-{2-[(3-aziridin-1-yl-1,4-dioxo-1,4-dihydro-
naphthalen-2-yl)thio]ethoxy}ethyl)thio]naphthoquinone
(AZ-1) had the most potent death effect on breast cancer
cells (BC-M1) and less cytotoxicity to normal fibroblast
cells (skin fibroblasts). In this study, we were interested in
determining the cytotoxicity of AZ-1 to our localized cell line
(BC-M1 cells) and to determine the mechanism by which
this occurs. We compared the death effect of two cell lines
(BC-M1 and the estrogen-receptor-positive cell line MCF-
7) induced by AZ-1, and also compared the cytotoxicity of
AZ-1 with two clinical anti-breast cancer therapies,
tamoxifen (aromatase inhibitors) and paclitaxel, in the cell
viability of BC-M1 cells.
Materials and methods
Materials
RPMI 1640 medium, DMEM medium, fetal bovine serum, 2
mM L-glutamine, MEM non-essential amino acid, trypsin-
EDTA solution, PBS, Hank's balanced salt solution, pencil-
lin-streptomycine and fungizone were purchased from
Gibco Laboratories (Grand Island, NY, USA). NaHCO3
-,
MTT, trypan blue, EDTA, propidium iodide, Hoechst
33258, paclitaxel and tamoxifen were purchased from
Sigma Chemical Co. (St Louis, MO, USA). The primary
antibodies of T-cell restricted intracellular antigen-related
protein (TIAR), pro-caspase and p53, cyclin-dependent
kinase (cdk) 2 and cyclin B were purchased from BD Trans-
duction Laboratories (BD Bioscience, Palo Alto, CA, USA).
Peroxidase-conjugated affinity-purified goat anti-mouse
IgG was purchased from Jackson Immuno Research Labo-
ratories (West Grove, PA, USA). The chamber slide was
purchased from NUNC (Roskilde, Denmark). All other
chemicals were purchased from Merck (Darmstadt, Ger-
many). AZ-1 was obtained from total synthesis in our labo-
ratory, was dissolved in dimethsulfoxide before
experimental use and was aliquoted to be stored at -20°C,
with stability for several years.
Methods
Human cell lines cultured
The BC-M1 (human breast adenocarcinoma) cell line was
cultured in RPMI 1640 medium with 10% fetal bovine
serum, 2 mM L-glutamine, and 25 mM Hepes. Skin fibrob-
lasts and MCF-7 cells were cultured in DMEM medium with
10% fetal bovine serum, 2 mM L-glutamine, and MEM non-
essential amino acid. The cell culture media for the two cell
lines all contained pencillin-streptomycine and fungizone.
All cells were incubated in a humidified atmosphere of 5%
CO2 at 37°C. Cell cultures were subcultured once or twice
weekly using trypsin-EDTA to detach the cell from their cul-
ture flask. The numbers of cells were counted after trypsini-
zation by a Neubauer hemocytometer (VWR Scientific
Corp., Philadelphia, PA, USA).
Cytotoxicity determined by MTT for cell viability
The MTT assay was performed according to the method of
Skehan and colleagues [19]. One day before drug applica-
tion, cells were seeded in 96-well flat-bottomed microtiter
plates (3000–5000 cells/well). Cells were incubated for
24 hours with various drugs, and applied as serial dilutions
(100 µl/well) at various concentrations. Twenty microliters
of MTT (5 mg/ml) were added to each well and incubated
for 4 hours at 37°C. The formazan product was dissolved
by adding 100 µl dimethylsulfoxide to each well, and the
plates were read at 550 nm. All measurements wereAvailable online http://breast-cancer-research.com/content/7/1/R19
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performed in triplicate and each experiment was repeated
at least three times. The IC50 value was calculated from the
50% formazan formation compared with a control without
addition of drugs.
Apoptoic body stained by Hoechst 33258
The cells were cultured in RPMI 1640 complete medium
for BC-M1 cells and in DMEM complete medium for MCF-
7 cells on a chamber slide (1 × 104 cells/ml). Various con-
centrations of AZ-1 compound were added and incubated
at 37°C. After 24 hours of incubation, the cultured medium
was removed and the cells were fixed by acetic acid/meth-
anol (1:3) solution for 10 min. In the following step, the fixed
solution was removed and cells were air-dried for another
10 min. The cell was stained by Hoechst 33258 stain solu-
tion (0.5 µg/ml in Hank's balanced salt solution) at room
temperature for 30 min. After staining, the solution was
removed, the cell was washed three times with distilled
water and then one drop of mounting solution (0.1 M citric
acid:0.2 M disodium phosphate:glycerol, 1:1:2) was added
before being covered by a cover slide. Apoptotic cells
showed blue, peripherally clumped or fragmented
chromatin.
Apoptosis analysis by flow cytometry
The apoptotic nuclei of BC-M1 cells induced by AZ-1 were
also identified by the flow cytometry analysis method as
described by Dive and colleagues with minor modification
[20]. The BC-M1 cells were treated with various concentra-
tions of AZ-1 for 24 hours. Cells were harvested and DNA
was stained with propidium iodide. The DNA content was
measured by flow cytometry (Becton Dickinson FACScan,
San Jose, CA, USA).
Western blot analysis
This analysis method was that according to Bacus and col-
leagues with slight modifications [21]. Briefly, cells were
collected from a 100 mm cultured dish after challenge by
various concentrations of AZ-1 compound at 24 hours. Cell
pellets were spun-down by centrifugation (1000 × g × 20
min). Pellets were resuspended in cold buffer (10 mM
HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithi-
othreitol, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM ben-
zamidine, 30 mg/ml leupeptin, 5 mg/ml aprotinin, and 5 mg/
ml pepstatin A; all from Sigma) and were incubated on ice
for 5 min and lysed by sonication. Cell lysate (25 µg) was
separated by 12% SDS-PAGE and transferred onto polyvi-
nylidene difluoride membranes (Amersham, Little Chalfont,
UK). Blots were incubated with blocking buffer (11 mM
Tris-vase [pH 7.4], 154 mM NaCl, and 5% skim milk),
washed by washing buffer (11 mM Tris-vase [pH 7.4], 154
mM NaCl, and 0.1% Tween-20) and incubated with spe-
cific antibodies to probe specific proteins. The primary anti-
bodies were from mouse anti-human monoclonal
antibodies (Imgenex Co., San Diego, CA, USA). The sec-
ondary antibody (Jackson ImmunoResearch Laboratories)
was conjugated with horseradish peroxidase at an appro-
priate dilution by blocking buffer. The dilution factors for the
primary and secondary antibodies were various (dependent
on different proteins) and 1:5000, respectively. The primary
antibodies used were a mouse monoclonal antibody to
GAPDH and β-actin with dilution factors 1:2000 (Biogen-
esis, Poole, UK) and 1:10,000 (Calbiochem, San Diego,
CA, USA), respectively. Immunodetection was carried out
using enhanced chemiluminescence (NEN, Boston, MA,
USA) detection system. Quantification of various protein
expressions were achieved by measuring the intensity of
chemiluminescence of the second antibody using a densi-
tometer (BioRad Gel Doc 2000 software, analyzed using
Gel Doc; BioRad Laboratories, Hercules, CA, USA) The
values in the relative expression-quantifying table of various
proteins represent the relative amounts of protein expres-
sion with respect to GAPDH or β-actin expression divided
by its control.
Caspase-3 activity assay
The BC-M1 cells were treated with various concentrations
of AZ-1 for 24 hours. The cells were harvested and washed
with PBS buffer twice. The caspase-3 activity of BC-M1
cells challenged by AZ-1 was measured by the CPP32/
caspase-3 protease colorimetric assay kit, with the assay
method according to the procedure described by the man-
ufacturer (Chemicon, Temecula, CA, USA). Briefly, the
cells were first lysed by cold lysis buffer (supplied by the
assay kit) for 10 min. The cell lysate was then centrifuged
to remove the cell debris, and the protein concentration
determined by Barford reagent (BioRad Laboratories). The
supernatant was ready to detect the caspase-3 activity.
Apoptosis analysis by 1H-NMR spectra
1H-NMR spectroscopy was performed in vitro using meth-
ods previously described by Francis and colleagues with
minor modification [22]. Briefly, 5 × 107 cells were har-
vested and washed twice with PBS medium made with
D2O (90% purity), suspended in a final volume of 500 µl,
and were placed immediately on ice until data acquisition.
Samples were analyzed on a 400 MHz high-resolution
Brucker CSI Omega spectrometer (Brucker, Karlsruhe,
Germany) at 18°C, with pulse acquisition, a 90° flip angle,
a repetition time of 10 s, 64 or 128 excitations (depending
on the desired signal-to-noise ratio), 8 k points, and a 5 kHz
bandwidth. A coaxial tube filled with trimethylsialoproponic
acid, 0.1% solution in D2O, was used as reference (0.0
ppm) for each experiment. The relative areas underneath
the CH2 and CH3 resonance curves (at 1.3 ppm and 0.9
ppm, respectively) were calculated by integration of the
proton spectrum using the trough between the CH2 and
CH3 resonances as a baseline reference.Breast Cancer Research    Vol 7 No 1    Yang et al.
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Results
The cytoxicity of AZ-1 to BC-M1 cells and MCF-7 cells
The cytotoxicities of the IC50 value in AZ-1 to BC-M1 cells
and MCF-7 cells were 0.51 µM and 0.57 µM in a dose-
dependent manner, respectively. The response of these
two cell lines (MCF-7 and BC-M1) to AZ-1 was very similar
to cell viability in a dose-dependent manner. In the normal
fibroblast cell (skin fibroblast) there was still a 90% survival
rate at 2 µM (Fig. 1). According to the time-dependent
treatment of AZ-1 using an IC50 concentration of 0.51 µM
to BC-M1 cells, the cell viability was less than 10% after 36
hours of treatment in a time-dependent manner (Fig. 2). The
two clinical therapies paclitaxel and taxmoxifen were com-
pared regarding cytoxicity in BC-M1 cells with AZ-1, and
the estrogen receptor antagonist taxmoxifen and AZ-1
were more potent than paclitaxel. The taxmoxifen had a low
IC50 value of 0.05 µM, which is lower than AZ-1, with a pla-
teau concentration from 0.05 µM to 2 µM (Fig. 3).
Apoptosis assay by flow cytometry and Hoechst staining
Analysis of the DNA content of cells was used to determine
whether cell apoptosis was induced by AZ-1. The data of
the sub-G1 area indicated that BC-M1 cells had a signifi-
cant population of cell apoptosis in the sub-G1 area on
treatment with AZ-1 for 24 hours compared with dimethyl-
sulfoxide alone (Fig. 4). The sub-G1 area started at 1.0 µM
AZ-1 and exhibited a large increase in apoptotic cells iden-
tified as subcellular populations with decreasing DNA. The
BC-M1 cells treated with 2.0 µM AZ-1 exhibited the largest
apoptotic area (29.2%). This is similar to the apoptotic bod-
ies observed using the Hoechst stain (Fig. 5). The Hoechst
staining method was used to identify the apoptotic nuclei in
BC-M1 cells and MCF-7 cells. Apoptotic cells that con-
tained the apoptotic bodies showed blue peripherally
clumped or fragmented chromatin, as indicated by arrows
in Figs 5 and 6. From the visual observation of the Hoechst
staining results, the BC-M1 cells treated with 2.0 µM had
the highest number of apoptotic bodies (Fig. 5). The
Figure 1
Bis-aziridinylnapthoquinone (AZ-1) inhibited the proliferation of three  cell lines, skin fibroblasts (SF), BC-M1 and MCF-7 Bis-aziridinylnapthoquinone (AZ-1) inhibited the proliferation of three 
cell lines, skin fibroblasts (SF), BC-M1 and MCF-7. Cells were seeded 
for 18 hours before the addition of AZ-1 with various concentrations. 
The death effects of these three cell lines induced by various concen-
trations of AZ-1 were compared by the MTT assay. The MTT assay was 
used to determine the cell viability after an additional 24 hours of cul-
ture. Data are from quadruplet wells and are representative of three 
separate experiments.
Figure 2
Bis-aziridinylnapthoquinone (AZ-1) inhibited the proliferation of cell line  BC-M1 Bis-aziridinylnapthoquinone (AZ-1) inhibited the proliferation of cell line 
BC-M1. Shown is the cell viability of BC-M1 cells at various times using 
the IC50 dose (0.51 µM) of AZ-1 challenge. The MTT assay was used to 
determine the cell viability. Data are from quadruplet wells and are rep-
resentative of three separate experiments.
0.0 0.5 1.0 1.5 2.0
0
20
40
60
80
100
BC-M1
MCF-7
SF
C
e
l
l
V
i
a
b
i
l
i
t
y
(
%
o
v
e
r
c
o
n
t
r
o
l
)
Concentration (µM)
0 1 02 03 04 05 0
0
20
40
60
80
100
C
e
l
l
v
i
a
b
i
l
i
t
y
(
%
o
v
e
r
c
o
n
t
r
o
l
)
Time (hours)
Figure 3
Comparison of the death effect of BC-M1 cells induced by various con- centrations of bis-aziridinylnapthoquinone (AZ-1), paclitaxel and  tamoxifen by the MTT assay Comparison of the death effect of BC-M1 cells induced by various con-
centrations of bis-aziridinylnapthoquinone (AZ-1), paclitaxel and 
tamoxifen by the MTT assay. The MTT assay was used to determine the 
cell viability after an additional 24 hours of culture. Data are from quad-
ruplet wells and are representative of three separate experiments.
0.0 0.5 1.0 1.5 2.0
0
20
40
60
80
100
AZ-1
Tamoxfine
Paclitaxel
C
e
l
l
v
i
a
b
i
l
i
t
y
(
%
o
v
e
r
c
o
n
t
r
o
l
)
Concentration (µM)Available online http://breast-cancer-research.com/content/7/1/R19
R23
formation of apoptotic bodies was observed obviously at
concentrations as low as 0.5 µM AZ-1 in MCF-7 cells (Fig.
6).
Tumor cell apoptosis associated with protein expression 
and caspase-3 activity
We next set out to determine whether the induction of BC-
M1 cell apoptosis by AZ-1 was associated with expression
of apoptosis-related proteins. We found that AZ-1 induced
changes in BC-M1 cell expression of the checkpoint pro-
tein p53 and the cell arrest protein p21 in a dose-related
manner (Fig. 7). The p53 protein showed increasing
expression from 11% to 43% at 0.5 µM and 1 µM AZ-1,
and then decreased to 31% at the 2 µM concentration of
AZ-1, and p21 protein increased from 6% to 22% from the
0.5 µM to 2 µM concentrations of AZ-1 added to BC-M1
cells for 24 hours compared with control, respectively. The
other proteins including TIAR, pro-caspase protein and cell
cdk2 also showed a dose-dependent decreasing manner
(Fig. 8). From the western blot results and the values in the
relative protein expression-quantifying table (Figs 7 and 8)
it was revealed that the expression of proteins was affected
by various concentrations of AZ-1 in BC-M1 cells after 24
hours of treatment, and these relative protein expressions
were compared with the control. The cdk2, pro-caspase
protein and TIAR were reduced to about 62%, 85% and
65%, and to 40%, 67% and 57% when BC-M1 cells
treated with 1 µM AZ-1 and 2 µM AZ-1 for 24 hours com-
pared with control, respectively. Based on the results of
western blot analysis in the expression of pro-caspase pro-
tein, we determined the enzyme activity of caspase-3 in
BC-M1 cells after challenge by various concentrations of
AZ-1 from 0.5 µM to 4 µM for 24 hours. The enzyme activity
of caspase-3 dose-dependently increased with concentra-
tions of AZ-1. The activity was more than twofold over the
control in BC-M1 cells after 3 µM AZ-1 treatment for 24
hours (Fig. 9).
Assay of the apoptosis signal by 1H-NMR
According to some previous reports, the ratio of the CH2
and CH3 peak area on the cell membrane was directly in
proportion with the signal of apoptosis. From our results we
also observed the same phenomena that the ratio of the
CH2 and CH3 peak area was increasing according to the
concentration of AZ-1 (Fig. 10). It was about 1.7-fold
higher than the control at 2 µM AZ-1 treatment in BC-M1
cells.
Discussion
Breast cancer is the most common malignancy in women,
and it is highly curable if diagnosed at early stage. It is now
well established that adjuvant systemic therapy improves
Figure 4
Apoptosis induced by bis-aziridinylnapthoquinone (AZ-1) Apoptosis induced by bis-aziridinylnapthoquinone (AZ-1). BC-M1 cells were treated in 24-hour culture with (a) dimethylsulfoxide control, (b) 0.2 µM 
AZ-1, (c) 1.0 µM AZ-1, or (d) 2.0 µM AZ-1 before propidium iodide staining and analysis of the DNA content. Apoptosis is apparent from the large 
population of cells with increased DNA content in the sub-G1 area (M1 area). FL2-H, fluorescence two-peak high.
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Figure 5
Apoptosis induced by bis-aziridinylnapthoquinone (AZ-1) in BC-M1  cells Apoptosis induced by bis-aziridinylnapthoquinone (AZ-1) in BC-M1 
cells. The BC-M1 cells were treated in 24-hour culture with (a) dimeth-
ylsulfoxide control, (b) 0.2 µM AZ-1, (c) 1.0 µM AZ-1, or (d) 2.0 µM 
AZ-1 before Hoechst staining and analysis of the DNA nuclei. Apop-
totic cells showed as blue, peripherally clumped or fragmented chroma-
tin as indicated by the arrows.
Figure 6
Apoptosis induced by bis-aziridinylnapthoquinone (AZ-1) in MCF-7  cells Apoptosis induced by bis-aziridinylnapthoquinone (AZ-1) in MCF-7 
cells. The MCF-7 cells were treated in 24-hour culture with (a) dimeth-
ylsulfoxide control, (b) 0.2 µM AZ-1, (c) 1.0 µM AZ-1, or (d) 2.0 µM 
AZ-1 before Hoechst staining and analysis of the DNA nuclei. Apop-
totic cells showed blue, peripherally clumped or fragmented chromatin 
as indicated by the arrows.
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Figure 7
Bis-aziridinylnapthoquinone (AZ-1) alters the expression of apoptotic  proteins p53 and p21 Bis-aziridinylnapthoquinone (AZ-1) alters the expression of apoptotic 
proteins p53 and p21. The protein expression of p53 and p21 were 
assessed by immunoblot. The BC-M1 cells were treated with various 
concentration of AZ-1 (lanes 1–4: 0.2 µM, 0.5 µM, 1.0 µM, and 2.0 
µM) for 24 hours and cell lysate was prepared for analysis. Lane 5, 
untreated control (C). β-actin was an internal control on BC-M1 cells.
Figure 8
Bis-aziridinylnapthoquinone (AZ-1) alters the expression of apoptotic  proteins Bis-aziridinylnapthoquinone (AZ-1) alters the expression of apoptotic 
proteins. The protein expression of T-cell restricted intracellular antigen-
related protein (TIAR), pro-caspase 3 and cyclin-dependent kinase 
(cdk2) were assessed by immunoblot. The BC-M1 cells were treated 
with various concentration of AZ-1 (lanes 2–4: 0.2 µM, 1.0 µM, and 2.0 
µM) for 24 hours and cell lysate was prepared for analysis. Lane 1, 
untreated control (C). GADPH was an interna l control on BC-M1 cells.
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survival in patients with early-stage breast cancer [23,24].
Treatment options for early-stage breast cancer include
chemotherapy (e.g. anthrocyclines, taxanes) and hormone
therapy (e.g. tamoxifen, aromatase inhibitor). Estrogen
mediates its functions through two specific intracellular
receptors, estrogen receptor alpha and estrogen receptor
beta, which act as hormone-dependent transcriptional reg-
ulators [25,26]. The estrogen receptor pathway plays a crit-
ical role in the pathophysiology of human breast cancer.
Overexpression of estrogen receptor alpha is a well-estab-
lished prognostic and predictive factor in breast cancer
patients. The prognostic significance of estrogen receptor
beta is not well defined [27-30].
Our previous study on the different series of bis-aziridinyl-
naphthoquinone compounds identified that they exhibit a
more potent response toward the solid tumors than the cir-
culation tumors [17]. This result was supported by other
reports that there are differences in the reductive
metabolism between the solid tumors and the circulation
tumors [2]. Considering the importance of all the cellular
reductases (e.g. NADPH cytochrome P450 reductase,
cytochrome b5 reductase, [NADP]H oxidoreductase,
NQO1) in response to the whole cellular reductive metab-
olism, these reductases are probably involved in bioactiva-
tion of AZ-1. The bioreductive drugs AZQ, mitomycin C and
E09, however, have been developed to exploit the oxygen
deficiency in the hypoxic fraction of solid tumors on the
premise that hypoxic cells should show a greater propen-
sity for reductive metabolism than well-oxygenated cells
[2,31-33].
The major events involved in tissue homeostasis are prolif-
eration, differentiation, and apoptosis. The processes of
cell reproduction normally take place through an ordered
process, generally known as the cell cycle. The tumor
suppressor gene p53 is a multifunctional protein mainly
responsible for maintaining genomic integrity, and it is the
most frequently mutated gene in human tumors [34]. In
response to DNA damage, aberrant growth signals, or
chemotherapeutic drugs, p53 is stabilized and induces
apoptosis and/or cell cycle arrest. While the mechanisms
of p53-dependent apoptosis are not understood well, p53-
dependent cycle arrest is primarily mediated by the cdk
inhibitor p21 [34-36]. p21 regulates the cellular repair
response to damaged DNA [37].
In the cytotoxicity results, AZ-1 induced the death effect of
BC-M1 cells and MCF-7 cells in a dose-dependent and
time-dependent manner in BC-M1 cells (Figs 1 and 2).
From the results shown in Fig. 3, the hormone antagonist
taxmoxifen and AZ-1 were more potent than paclitaxel to
our local cell line BC-M1. This indicates that the BC-M1
cell is more sensitive to the hormone antagonist drug and
our bioreductive compound AZ-1 than to a nonhormone
antagonist such as paclitaxel. We assumed that the BC-M1
cell is an estrogen receptor-positive cell line. According to
the results of Figs 4 and 5, the apoptosis phenomena were
observed in BC-M1 cells induced by AZ-1 for 24 hours.
We saw the apoptotic bodies increasing in direct
proportion with the concentration of AZ-1 based on the
sub-G1 area measurement and Hoechst staining (Figs 4
and 5). The apoptotic bodies were increasing slightly in 0.5
Figure 9
The enzyme activity of caspase 3 in BC-M1 cells was induced by bis- aziridinylnapthoquinone (AZ-1) The enzyme activity of caspase 3 in BC-M1 cells was induced by bis-
aziridinylnapthoquinone (AZ-1). Cells were seeded for 24 hours before 
the addition of AZ-1 in various concentrations. The cell lysate was pre-
pared for analysis by a CPP32/caspase 3 colorimetric assay kit accord-
ing to the manufacturer's instructions. The enzyme activity is shown as 
the fold increase relative to the control.
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Figure 10
Plot of the ratio of CH2/CH3 peak area according to NMR spectra as  the dose of bis-aziridinylnapthoquinone (AZ-1)-treated BC-M1 cells Plot of the ratio of CH2/CH3 peak area according to NMR spectra as 
the dose of bis-aziridinylnapthoquinone (AZ-1)-treated BC-M1 cells. 
Cells were seeded for 24 hours before the addition of AZ-1 in various 
concentrations. The ratio of CH2/CH3 signal intensity was plotted 
against the various concentrations of AZ-1.
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µM AZ-1, and were most abundant at a concentration of
2.0 µM. The apoptotic bodies were also observed in MCF-
7 cells after treatment by AZ-1 for 24 hours (Fig. 6). For the
mechanism of the apoptotic pathway, we found that p53
might be involved in the death effect of BC-M1 cells
induced by the bioreductive compound AZ-1 in this study.
Figure 7 shows that the expression of the p53 protein of
BC-M1 cells was upregulated from 0.5 µM, was highest at
1.0 µM and downregulated at 2 µM AZ-1 for a 24-hour
challenge. The response of the expression sequence in
p21 protein was upregulation from 1.0 µM to 2.0 µM AZ-1
treatment to BC-M1 cells, which was later than for p53 pro-
tein. The p21 protein is the inhibitor of cdk2, the results of
Fig. 8 showing that it was decreasing to 40% of the cdk2
at 2.0 µM AZ-1 and was without any disturbance to cdk2
expression in 0.5 µM AZ-1.
TIAR is a membrane of RNA recognition motif-type RNA-
binding protein and also regulates the general translational
arrest that accompanies environmental stress [38]. In the
roles of the RNA-binding protein, TIAR involved the con-
nections between the eukaryotic initiation factor kinase sys-
tem, mRNA stability, and cellular chaperone levels [39,40].
Mutant mice lacking TIAR exhibit partial embryonic lethality
and defective germ-cell maturation, implicating this protein
in certain aspects of vertebrate development [41]. In DT40
cells, TIAR is also required for cell viability that involved the
splicing of the exons [42]. In our results, the expression of
TIAR protein was decreased with the concentrations of AZ-
1 increasing in BC-M1 cells. We therefore proposed that
TIAR was involved in the death effect of BC-M1 cells
induced by AZ-1, which might play a role in cell viability,
without direct proportion to apoptosis correlation.
According to the report of Schmidt and colleagues, p53
expression was correlated with the resistance against pacl-
itaxel [43]. From this report, none of the tumors with p53
expression (11 patients) responded to paclitaxel. In con-
trast, 10 of the 22 patients without p53 expression showed
an objective response. This phenomena was also sup-
ported by the report of Takara and colleagues [44],
whereby the doses of paclitaxel used in BC-M1 cells are
much higher than the usual IC50 values for most breast can-
cer cell lines reported in the literature (Fig. 3). This was also
supported by the data from our results (Fig. 7) that the p53
protein really existed in BC-M1 cells, and with function. The
report from Zhang and colleagues failed to detect the p53
protein in normal breast epithelial cells, and p53 positivity
was 24% and 30% in intraductal and invasive cancer tis-
sues, respectively [45]. The p53 protein could therefore be
detected in tumor cells such as BC-M1 cells in untreated
conditions, as in our results.
Caspases are a large family of cysteine proteases, most of
them playing central roles in the execution of apoptosis
[46]. The pro-caspase protein was in its inactive form when
the cell was in the rest state and the protein expression was
decreasing to convert to the active form of caspase-3 in the
process of apoptosis [47]. In our result, the expression of
pro-caspase protein was in inverse proportion to the con-
centrations of AZ-1 (Fig. 8, lane 2), and compared the
enzyme activity assay of caspase-3 that was in direct pro-
portion to AZ-1 concentration treatment to BC-M1 cells for
24 hours, as observed in Fig. 9. The apoptosis pathway of
BC-M1 cells induced by AZ-1 compound was mediated by
caspase-3. In this study, we also approached the apoptosis
phenomena by the NMR spectra method. Some reports
provided evidence that NMR spectroscopy allows the early
detection (after 6 hours) of apoptosis-induced cellular
changes in cells by observing signals from small and mobile
molecular species, particularly the ratio of intensities of the
CH2 and CH3 resonance [22,48]. Figure 10 shows that we
observed that the ratio of CH2 and CH3 in BC-M1 cells
induced by AZ-1 for 24 hours was also in direct proportion
with the concentration of AZ-1. This is also one of the
pieces of evidence to prove the apoptosis phenomena in
BC-M1 cells induced by AZ-1.
Conclusion
The apoptosis pathway in BC-M1 cells induced by various
concentrations of AZ-1 was initially triggered by the activa-
tion of p53 protein and then upregulation of the p21 protein
to inhibit the cyclin kinase cdk2 expression to arrest BC-M1
cell temporality and, finally, into the apoptosis process. In
BC-M1 cells, the arrest and apoptosis processes, the acti-
vation of caspase-3 activity, apoptotic body formation, the
ratio of CH2 and CH3 increasing and the expression of the
RNA-binding protein TIAR decreasing were all involved in
the death effect of BC-M1 cells induced by this bioreduc-
tive compound. From this study, AZ-1 could be used as a
cocktail in combination with other anti-breast cancer drugs
to cure the hypoxia tumor tissue of breast cancer patients
to prevent cancer cell recurrence.
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